Trial Profile
A Phase I, Prospective, Open-Label, Comparison Study of Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Cancer of the the Endometrium Who Are Undergoing Lymph Node Dissection
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions
- 10 Oct 2018 Status changed from recruiting to discontinued.
- 06 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Nov 2017.
- 06 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.